Devyser Diagnostics AB (DVYSR) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Devyser Diagnostics AB stock SEK 19.58, price SEK 64.80, that is 69.8% below the price, quality 65 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
59‑month range kr 49.75 – kr 157.80 · fair‑value band kr 13.95 – kr 29.73 · the kr 64.80 price screens above the kr 19.58 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Devyser Diagnostics in your weekly email
Every Wednesday you see whether Devyser Diagnostics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa.
Show moreShow less
It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results.
The company was incorporated in 2004 and is headquartered in Årsta, Sweden.
Stock analysis
Devyser Diagnostics AB (DVYSR) currently trades at kr 64.80, while our model-based Fair Value estimate is kr 19.58, 70% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 22.83 per share, and 0 of the 14 models we run sit above the kr 64.80 price.
Bear case: the Asset-Based group reads lowest at kr 5.26, and 14 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: kr 13.95 (bear) to kr 29.73 (bull), the price of kr 64.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Devyser Diagnostics AB reported revenue of 251M SEK in FY2025 versus 93.5M SEK in FY2021, a compound +27.9%/yr. Reported net income was −8.4M SEK in FY2025.
Key figures
Market cap 1.1B SEK (≈ $110M) Micro · P/E ratio 42.6 · P/S ratio 4.29 · EPS (TTM) kr 1.52 · Net margin 10.1% · Return on equity 7.0% · Return on assets (EBIT) −7.4% (5-year average) · Operating margin 12.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 46% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −70%, DVYSR screens richer than that median.
Fair Value models
Bearkr 13.95Fair Value kr 19.58Bullkr 29.73
Price kr 64.80 · Downside -69.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 1.30 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+15.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.7%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.6%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10.6% (2020) → 4.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+57.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +54.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score65 · Above median
Fair Value upside−69.8% · Bottom 25%
Profitability
Return on equity (12 months)7.0% · Above median
Return on assets−1.8% · Below median
Net margin (12 months)10.1% · Above median
Operating margin (12 months)12.1% · Above median
Growth and dividend
Revenue growth (quarter YoY)5.9% · Below median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Devyser Diagnostics AB Fair Value". https://www.fairvalue-calculator.com/stock/DVYSR
Frequently asked questions
Is Devyser Diagnostics AB (DVYSR) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of kr 19.58 versus a price of kr 64.80, about 70% lower (overvalued).
What is the fair value of DVYSR?
Our model-based fair value for Devyser Diagnostics AB is kr 19.58 (as of Nov 6, 2026), built from audited fundamentals. The current price: kr 64.80.
What is the quality score of DVYSR?
Devyser Diagnostics AB has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Devyser Diagnostics AB (DVYSR)?
Our model-based price target is the fair value of kr 19.58 (as of Nov 6, 2026) from 14 valuation models. Cautious scenario kr 13.95, optimistic scenario kr 29.73. It is a calculation from audited fundamentals, not an analyst target.
What is the Devyser Diagnostics AB stock forecast for 2026?
Our models put fair value at kr 19.58, about 70% lower versus a price of kr 64.80 (overvalued). Cautious scenario kr 13.95, optimistic scenario kr 29.73. The calculation is refreshed regularly with new filings.
What is the revenue of Devyser Diagnostics AB (DVYSR)?
Devyser Diagnostics AB reported trailing-twelve-month revenue of about 254M SEK (latest available figure, as of Nov 6, 2026).
What growth is priced into Devyser Diagnostics AB (DVYSR)?
For today's price to be fair in a discounted-cash-flow model, Devyser Diagnostics AB would have to grow free cash flow by +57.3 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +30.7 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of DVYSR use?
Our models discount Devyser Diagnostics AB at 11.9 %: a base by market capitalisation (micro), damped by beta 0.80, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Devyser Diagnostics AB that is +57.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has Devyser Diagnostics AB (DVYSR) delivered so far?
Over the past 5 years revenue at Devyser Diagnostics AB grew +30.7 % a year. The price currently implies free-cash-flow growth of +57.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Devyser Diagnostics AB (DVYSR) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Devyser Diagnostics AB (+57.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Devyser Diagnostics AB (DVYSR)?
The free-cash-flow yield on the price is 0.62 %: that much free cash flow Devyser Diagnostics AB produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Devyser Diagnostics AB (DVYSR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Devyser Diagnostics AB it is kr 19.58 per share (as of Nov 6, 2026), against a price of kr 64.80. It is the blended result of 14 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Devyser Diagnostics AB stock overvalued or undervalued in 2026?
As of Nov 6, 2026, DVYSR trades above its calculated fair value: price kr 64.80, fair value kr 19.58, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DVYSR?
No. The price is what the market pays today (kr 64.80); the fair value is what the company's own numbers justify (kr 19.58). For Devyser Diagnostics AB the two are kr 45.22 per share apart. That gap is exactly why we show both numbers side by side.
How much is Devyser Diagnostics AB worth?
The market values Devyser Diagnostics AB at about 1.1B SEK (market capitalisation, as of Nov 6, 2026). Per share that is kr 64.80; our models calculate a fair value of kr 19.58 per share.
What do the bullish and bearish scenarios say about DVYSR?
Our models span a range for Devyser Diagnostics AB: cautious scenario kr 13.95, base kr 19.58, optimistic kr 29.73 per share (as of Nov 6, 2026, price kr 64.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DVYSR?
Devyser Diagnostics AB trades at a price-to-earnings ratio of 42.6 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 19.58 is built from several models across several years. Other multiples: P/B 3.1, P/S 4.3, EV/EBITDA 22.6.
How solid is the balance sheet of Devyser Diagnostics AB (DVYSR)?
Balance-sheet figures for Devyser Diagnostics AB (as of Nov 6, 2026): return on equity 7.0%, debt of 0.00 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is DVYSR from its 52-week high?
Devyser Diagnostics AB trades at kr 64.80, about 46% below its 52-week high of kr 120.00 and 30% above the low of kr 49.75 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 19.58 is for.
Which stocks are comparable to Devyser Diagnostics AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Devyser Diagnostics AB stock attractive at the current price?
The data as of Nov 6, 2026: price kr 64.80, calculated fair value kr 19.58 (−70%), Quality Score 65/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DVYSR calculated?
We run Devyser Diagnostics AB through 14 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of kr 19.58 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Devyser Diagnostics AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Devyser Diagnostics AB (DVYSR)?
The closing price on Nov 6, 2026 was kr 64.80. Our model-based fair value is kr 19.58, about 70% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Devyser Diagnostics AB right now?
The price sits above even our optimistic bull case (kr 29.73). The favourable scenario is already priced in. Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 13.95 to kr 29.73) leaves room in how you read the outcome.
Key figures of Devyser Diagnostics AB
How large is the market capitalisation of Devyser Diagnostics AB (DVYSR)?
The market capitalisation of Devyser Diagnostics AB is 1.1B SEK (≈ $110M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Devyser Diagnostics AB (DVYSR)?
The price-to-sales ratio of Devyser Diagnostics AB is 4.29 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Devyser Diagnostics AB (DVYSR)?
Earnings per share at Devyser Diagnostics AB are kr 1.52 (price ÷ EPS = P/E 42.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Devyser Diagnostics AB (DVYSR)?
The net margin of Devyser Diagnostics AB is 10.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Devyser Diagnostics AB (DVYSR)?
The return on equity (ROE) of Devyser Diagnostics AB is 7.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Devyser Diagnostics AB (DVYSR)?
On an EBIT basis the return on assets of Devyser Diagnostics AB is −7.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Devyser Diagnostics AB (DVYSR)?
The operating margin of Devyser Diagnostics AB is 12.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Devyser Diagnostics AB (DVYSR)?
Revenue at Devyser Diagnostics AB is growing +5.9% versus a year earlier (3y avg +25.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Devyser Diagnostics AB (DVYSR)?
Earnings per share at Devyser Diagnostics AB are growing +21.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Devyser Diagnostics AB (DVYSR) carry?
The net debt of Devyser Diagnostics AB is 11.9M SEK (fiscal year 2025, ≈ 1.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Devyser Diagnostics AB in the live analysis
One click puts Devyser Diagnostics AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026